600276 恒瑞医药
午间休市 07-21 11:29:59
资讯
新帖
简况
恒瑞医药(01276)截至7月19日累计回购1375.02万股A股
智通财经 · 07-19 19:31
恒瑞医药(01276)截至7月19日累计回购1375.02万股A股
恒瑞医药(01276)7月17日斥资1508.88万元回购28万股A股
智通财经 · 07-17
恒瑞医药(01276)7月17日斥资1508.88万元回购28万股A股
恒瑞医药：HRS9531注射液获临床试验批准
南方财经网 · 07-16
恒瑞医药：HRS9531注射液获临床试验批准
恒瑞医药(600276.SH)：HRS-8797片获得药物临床试验批准通知书
智通财经 · 07-15
恒瑞医药(600276.SH)：HRS-8797片获得药物临床试验批准通知书
恒瑞医药(01276)：HRS-7058胶囊被纳入突破性治疗品种名单
智通财经 · 07-13
恒瑞医药(01276)：HRS-7058胶囊被纳入突破性治疗品种名单
恒瑞医药：SHR-3079注射液获临床试验批准
南方财经网 · 07-13
恒瑞医药：SHR-3079注射液获临床试验批准
明星肿瘤疗法出海美国第三次遇阻，恒瑞称未涉及有效性等问题
澎湃新闻 · 07-10
明星肿瘤疗法出海美国第三次遇阻，恒瑞称未涉及有效性等问题
恒瑞医药(01276)收到关于注射用卡瑞利珠单抗的完整回复信
智通财经 · 07-10
恒瑞医药(01276)收到关于注射用卡瑞利珠单抗的完整回复信
恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题
第一财经 · 07-10
恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题
瑞银：恒瑞医药(01276)减重药HRS-7535临床数据正面 估值吸引重申“买入”
智通财经 · 07-09
瑞银：恒瑞医药(01276)减重药HRS-7535临床数据正面 估值吸引重申“买入”
大行评级丨瑞银：恒瑞医药HRS-7535减重III期临床试验达成主要终点，维持“买入”评级
格隆汇 · 07-09
大行评级丨瑞银：恒瑞医药HRS-7535减重III期临床试验达成主要终点，维持“买入”评级
研报掘金丨银河证券：维持恒瑞医药“推荐”评级，创新管线持续兑现，BC矩阵进一步完善
格隆汇 · 07-08
研报掘金丨银河证券：维持恒瑞医药“推荐”评级，创新管线持续兑现，BC矩阵进一步完善
恒瑞医药：子公司SHR-4685注射液临床试验获批
财中社 · 07-07
恒瑞医药：子公司SHR-4685注射液临床试验获批
多地三甲医院药房化疗药环磷酰胺缺货，药企：正常供应中，发到医院还需时间
红星资本局 · 07-06
多地三甲医院药房化疗药环磷酰胺缺货，药企：正常供应中，发到医院还需时间
恒瑞医药：公司将持续优化税务合规管理体系，坚守经营合规底线
证券日报 · 07-03
恒瑞医药：公司将持续优化税务合规管理体系，坚守经营合规底线
恒瑞医药(01276)：截至6月30日累计回购1347.02万股A股
智通财经 · 07-02
恒瑞医药(01276)：截至6月30日累计回购1347.02万股A股
恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评
财中社 · 07-02
恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评
恒瑞医药：SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液获临床试验批准
南方财经网 · 07-02
恒瑞医药：SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液获临床试验批准
港股异动 | 恒瑞医药(01276)盘中涨超6% 近期创新药艾瑞利®新增适应症 国际化出海成果颇丰
智通财经 · 07-02
港股异动 | 恒瑞医药(01276)盘中涨超6% 近期创新药艾瑞利®新增适应症 国际化出海成果颇丰
恒瑞医药旗下恒宜®获批在中国上市，作为创新性环孢素滴眼液用于治疗干眼症
美股速递 · 06-30
恒瑞医药旗下恒宜®获批在中国上市，作为创新性环孢素滴眼液用于治疗干眼症
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.14,"timestamp":1784604599000,"preClose":55.57,"halted":0,"volume":59849806,"delay":0,"changeRate":-0.0257,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"午间休市","change":-1.43,"latestTime":"07-21 11:29:59","open":55.99,"high":55.99,"low":53.76,"amount":3266000000,"amplitude":0.0401,"askPrice":54.15,"askSize":105,"bidPrice":54.14,"bidSize":6,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784610000000},"marketStatusCode":3,"adr":0,"adjPreClose":55.57,"symbolType":"stock","openAndCloseTimeList":[[1784597400000,1784604600000],[1784610000000,1784617200000]],"highLimit":61.13,"lowLimit":50.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.8,"roa":"--","peRate":44.257337,"roe":"4.15%","epsLYR":1.19,"committee":-0.138983,"marketValue":359338000000,"turnoverRate":0.0094,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":55.7,"timestamp":1784605752327,"preClose":57.5,"halted":0,"volume":1869683,"delay":0,"premium":"-11.20"},"floatMarketCap":345359000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2652251979","title":"恒瑞医药(01276)截至7月19日累计回购1375.02万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652251979","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652251979?lang=zh_cn&edition=full","pubTime":"2026-07-19 19:31","pubTimestamp":1784460711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至2026年7月19日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1375.02万股，已回购股份占公司总股本的比例为0.21%，购买的最高价为人民币 70.00 元/股，最低价为人民币 45.30 元/ 股，已支付的总金额为人民币8.53亿元(不含交易费用)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","LU2488822045.USD","BK0188","LU2097828714.EUR","BK0183","399300","LU1255011170.USD","BK0012","159982","LU0405327148.USD","BK0196","LU1997245094.SGD","LU1580142542.USD","LU2097828805.USD","LU2543165471.USD","LU2580892862.HKD","LU0359201885.HKD","LU2097828474.EUR","LU0405327494.USD","LU2495084118.USD","LU1064130708.USD","BK0239","LU1064131003.USD","BK0028","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","LU2328871848.SGD","LU2097828631.EUR","LU1146622755.USD","LU1781817850.SGD","LU1969619763.USD","LU1655091616.SGD","LU0359202008.SGD","LU2580892789.USD","01276","LU1997245177.USD","LU1023057109.AUD","LU1820825898.SGD","LU2148510915.USD","600276","BK0060","BK1191","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652340959","title":"恒瑞医药(01276)7月17日斥资1508.88万元回购28万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652340959","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652340959?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:04","pubTimestamp":1784279092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年7月17日，该公司斥资1508.88万元回购28万股A股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","399300","LU1023057109.AUD","LU2097828805.USD","LU2289578879.USD","BK0188","LU1997245177.USD","LU1969619763.USD","BK0239","LU1255011170.USD","LU0359201612.USD","LU1655091616.SGD","LU1781817850.SGD","LU1820825898.SGD","LU2495084118.USD","BK0183","LU1146622755.USD","BK0028","LU1064131003.USD","BK0012","BK0060","LU0405327148.USD","LU2097828557.USD","LU0359201885.HKD","LU1064130708.USD","LU2097828631.EUR","01276","600276","LU0405327494.USD","BK0196","BK1191","LU1328615791.USD","LU1580142542.USD","LU2488822045.USD","LU2580892789.USD","LU2148510915.USD","159982","LU1997245094.SGD","LU1997244956.HKD","LU2580892862.HKD","LU2543165471.USD","LU2328871848.SGD","LU2097828714.EUR","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410634","title":"恒瑞医药：HRS9531注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410634","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651410634?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:06","pubTimestamp":1784192760,"startTime":"0","endTime":"0","summary":"南财智讯7月16日电，恒瑞医药公告，HRS9531注射液收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意该药在肥胖合并膝骨关节炎成人患者中开展III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163809110193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","LU2328871848.SGD","LU1064130708.USD","LU1328615791.USD","LU1580142542.USD","LU2097828805.USD","LU2097828474.EUR","LU2097828631.EUR","LU0405327494.USD","01276","BMED","LU1997245177.USD","LU2289578879.USD","BK1191","LU2097828714.EUR","BK0012","LU1997244956.HKD","LU2580892789.USD","BK0028","LU2097828557.USD","LU0405327148.USD","IBBQ","LU2543165471.USD","LU2488822045.USD","BK0188","LU1655091616.SGD","LU1969619763.USD","600276","BK0183","LU1023057109.AUD","LU1064131003.USD","LU2148510915.USD","LU1781817850.SGD","LU2495084118.USD","LU0359201612.USD","LU1997245094.SGD","LU1255011170.USD","LU2580892862.HKD","BK0196","BK0060","BK0239","LU1820825898.SGD","LU0359202008.SGD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455962","title":"恒瑞医药(600276.SH)：HRS-8797片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455962","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455962?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:49","pubTimestamp":1784105383,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-8797片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-8797片是公司自主研发的治疗特应性皮炎的1类创新药，经查询，全球范围内暂无同类药物获批上市。截至目前，HRS-8797片相关项目累计研发投入约为3,290万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU2097828805.USD","LU0359202008.SGD","LU2543165471.USD","IBBQ","LU2495084118.USD","LU1580142542.USD","LU2097828474.EUR","BK0060","LU2148510915.USD","LU1064130708.USD","BMED","01276","LU1820825898.SGD","LU0405327494.USD","LU1255011170.USD","LU1997245177.USD","LU1328615791.USD","LU1969619763.USD","BK0196","BK0239","LU0359201612.USD","LU2097828631.EUR","LU2289578879.USD","LU2580892789.USD","LU2488822045.USD","LU2097828714.EUR","BK1191","BK0012","600276","LU2328871848.SGD","LU1997244956.HKD","BK0183","BK0188","LU0359201885.HKD","LU1655091616.SGD","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU0405327148.USD","LU1023057109.AUD","LU2097828557.USD","LU2580892862.HKD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651116701","title":"恒瑞医药(01276)：HRS-7058胶囊被纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2651116701","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651116701?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:29","pubTimestamp":1783945789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，近日，公司的HRS-7058胶囊被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，HRS-7058是一种新型、高效、选择性的小分子共价抑制剂，拟用于治疗KRAS G12C突变的晚期实体肿瘤。2025年ESMO大会上，HRS-7058用于KRAS G12C突变晚期实体瘤的I期、多中心、首次人体研究以口头报告形式公布 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","LU2580892862.HKD","LU2580892789.USD","LU2289578879.USD","BK0196","BK0188","LU0359201612.USD","BK0060","LU1064130708.USD","LU2495084118.USD","LU2097828474.EUR","LU2148510915.USD","LU1146622755.USD","LU2097828557.USD","LU1064131003.USD","LU2328871848.SGD","LU0405327148.USD","LU1023057109.AUD","LU2488822045.USD","LU2097828714.EUR","LU2543165471.USD","LU1255011170.USD","LU1997245094.SGD","600276","BK0028","BK0239","01276","LU1997244956.HKD","LU2097828631.EUR","LU0359202008.SGD","LU0405327494.USD","BK0183","LU0359201885.HKD","LU1580142542.USD","LU1328615791.USD","BK1191","LU1655091616.SGD","LU1781817850.SGD","LU1820825898.SGD","LU1969619763.USD","LU2097828805.USD","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651197900","title":"恒瑞医药：SHR-3079注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651197900","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651197900?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:07","pubTimestamp":1783933620,"startTime":"0","endTime":"0","summary":"南财智讯7月13日电，恒瑞医药公告，SHR-3079注射液收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意该药在成人系统性红斑狼疮、成人类风湿关节炎适应症中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607133803860814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245177.USD","BK1191","LU2097828631.EUR","LU2488822045.USD","LU2097828805.USD","LU2289578879.USD","BK0060","01276","LU1146622755.USD","LU0405327148.USD","LU1023057109.AUD","LU0359201612.USD","LU1820825898.SGD","LU1255011170.USD","LU2543165471.USD","BK0196","BMED","LU2097828474.EUR","LU1997244956.HKD","BK0028","LU2328871848.SGD","LU1781817850.SGD","BK0012","LU1655091616.SGD","LU0405327494.USD","BK0239","IBBQ","LU1064131003.USD","LU1328615791.USD","LU2580892862.HKD","600276","BK0183","BK0188","LU2495084118.USD","LU2580892789.USD","LU1064130708.USD","LU2097828557.USD","LU0359202008.SGD","LU2148510915.USD","LU1580142542.USD","LU0359201885.HKD","LU2097828714.EUR","LU1997245094.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650187333","title":"明星肿瘤疗法出海美国第三次遇阻，恒瑞称未涉及有效性等问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650187333","media":"澎湃新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650187333?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:30","pubTimestamp":1783683000,"startTime":"0","endTime":"0","summary":"明星肿瘤疗法出海美国第三次遇阻，恒瑞称未涉及有效性等问题","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103802063375.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103802063375.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","LU2097828474.EUR","LU1820825898.SGD","LU1328615791.USD","BK1191","LU2148510915.USD","LU0359201885.HKD","LU2580892789.USD","BK0012","LU2097828631.EUR","BK4588","LU1064131003.USD","BK4585","LU2580892862.HKD","BK0239","IE00BFMHRM44.USD","LU2495084118.USD","BK0188","CRL","LU1781817850.SGD","LU1997245094.SGD","LU1023057109.AUD","LU0359201612.USD","LU2328871848.SGD","LU2097828805.USD","LU0128526141.USD","LU0359202008.SGD","LU1655091616.SGD","BK4530","01276","BK0196","LABU","LU1969619763.USD","LU2097828714.EUR","LU2289578879.USD","LU2543165471.USD","LU1064130708.USD","LU2097828557.USD","LU0390134368.USD","BK0060","BK4121","LU0405327148.USD","LU0405327494.USD","BK0028","LU1146622755.USD","600276","LU1997245177.USD","LU0029874061.USD","LU1815336091.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650072159","title":"恒瑞医药(01276)收到关于注射用卡瑞利珠单抗的完整回复信","url":"https://stock-news.laohu8.com/highlight/detail?id=2650072159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650072159?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:01","pubTimestamp":1783666881,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司收到美国食品药品监督管理局关于注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请的完整回复信。此次 CRL 未涉及对产品临床研究数据、安 全 性 及 有 效 性 方 面 的 问 题 。公 司 将 积 极 与 FDA 及 合 作 伙 伴 Elevar Therapeutics 进行密切沟通，以明确后续的申报计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1820825898.SGD","LU1655091616.SGD","LU0359202008.SGD","LU2495084118.USD","LU1997245177.USD","LU2580892789.USD","01276","LU1255011170.USD","LU1997245094.SGD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","BK0028","LU1328615791.USD","LU1064131003.USD","LU2328871848.SGD","LU1146622755.USD","LU0405327148.USD","LU2097828474.EUR","LU1064130708.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK1191","LU1781817850.SGD","LU2289578879.USD","LU0359201612.USD","LU2488822045.USD","600276","LU2097828714.EUR","LU2543165471.USD","LU2580892862.HKD","LU0405327494.USD","BK0012","BK0239","LU2097828557.USD","LU2097828631.EUR","BK0183","LU0359201885.HKD","LU2097828805.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907155","title":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907155","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907155?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:43","pubTimestamp":1783665784,"startTime":"0","endTime":"0","summary":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801735795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801735795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","600276","01276","LU1580142542.USD","LU1781817850.SGD","LU0359201612.USD","LU1969619763.USD","LU2148510915.USD","BK0060","LU2580892862.HKD","LU2488822045.USD","LU0359201885.HKD","BK1191","LU1255011170.USD","LU1997245094.SGD","LU2097828557.USD","BK0183","BK0028","LU2543165471.USD","LU2289578879.USD","LU2580892789.USD","LU0405327494.USD","BK0196","LU2495084118.USD","LU1169590202.USD","LU0405327148.USD","LU1328615791.USD","BK4023","LU2097828631.EUR","BK0239","LU2097828805.USD","LU0359202008.SGD","PD","LU2097828714.EUR","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1023057109.AUD","LU1997244956.HKD","LU1169589451.USD","LU2097828474.EUR","LU1997245177.USD","LU1064131003.USD","BK0012","LU1146622755.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650405109","title":"瑞银：恒瑞医药(01276)减重药HRS-7535临床数据正面 估值吸引重申“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2650405109","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650405109?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:15","pubTimestamp":1783588554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，恒瑞医药(01276)HRS-7535减重III期临床试验达成主要终点，公司预期将于今年提交中国新药上市申请(NDA)。该行认为HRS-7535临床数据表现正面，截至第44周末，180mg每日一次剂量组录得9.8%的体重降幅，减重效果仍未见平台化，且药物耐受性良好。该行预测，恒瑞GLP-1产品组合于中国市场销售额至2035年有望达59亿元人民币。瑞银指出，公司两项针对2型糖尿病的国内III期临床试验已成功达成主要终点。瑞银维持恒瑞医药“买入”评级，H股目标价97.4港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU1023057109.AUD","LU1255011170.USD","LU2488822045.USD","BK0196","BK0012","LU1064130708.USD","LU2543165471.USD","LU2097828805.USD","LU1820825898.SGD","BK0188","LU2289578879.USD","LU0359201885.HKD","LU2097828631.EUR","BK0060","BK0183","BK1191","LU1781817850.SGD","LU2328871848.SGD","LU2495084118.USD","LU1969619763.USD","BK0028","LU2097828557.USD","LU1997245177.USD","LU0359201612.USD","LU0405327148.USD","LU0359202008.SGD","LU1146622755.USD","LU1997245094.SGD","LU2580892789.USD","LU1580142542.USD","LU2580892862.HKD","LU2097828474.EUR","BK0239","LU1328615791.USD","LU0405327494.USD","LU1064131003.USD","600276","LU1655091616.SGD","LU1997244956.HKD","LU2148510915.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650446639","title":"大行评级丨瑞银：恒瑞医药HRS-7535减重III期临床试验达成主要终点，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2650446639","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650446639?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:36","pubTimestamp":1783582577,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0196","LU1820825898.SGD","LU1655091616.SGD","LU0359202008.SGD","LU2495084118.USD","LU1997245177.USD","LU2580892789.USD","01276","LU1255011170.USD","LU1997245094.SGD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","BK0028","LU1328615791.USD","LU1064131003.USD","LU2328871848.SGD","LU1146622755.USD","LU0405327148.USD","LU2097828474.EUR","LU1064130708.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK1191","LU1781817850.SGD","LU2289578879.USD","LU0359201612.USD","LU2488822045.USD","600276","LU2097828714.EUR","LU2543165471.USD","LU2580892862.HKD","LU0405327494.USD","BK0012","BK0239","LU2097828557.USD","LU2097828631.EUR","BK0183","LU0359201885.HKD","LU2097828805.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649965126","title":"研报掘金丨银河证券：维持恒瑞医药“推荐”评级，创新管线持续兑现，BC矩阵进一步完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2649965126","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649965126?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:31","pubTimestamp":1783495867,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1997244956.HKD","LU1820825898.SGD","LU1146622755.USD","LU2097828714.EUR","LU1997245094.SGD","LU1064131003.USD","LU2097828631.EUR","LU1969619763.USD","LU1655091616.SGD","LU0405327148.USD","LU1997245177.USD","LU2097828805.USD","LU2580892789.USD","LU1781817850.SGD","LU2495084118.USD","BK0060","BK0188","LU2097828474.EUR","BK0183","LU2488822045.USD","LU0405327494.USD","LU1328615791.USD","BK0012","LU2097828557.USD","LU1580142542.USD","BK0196","LU2148510915.USD","BK0239","LU2328871848.SGD","LU2580892862.HKD","BK0028","LU2289578879.USD","LU1255011170.USD","600276","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649898554","title":"恒瑞医药：子公司SHR-4685注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2649898554","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649898554?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:10","pubTimestamp":1783415400,"startTime":"0","endTime":"0","summary":"7月7日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607073796801870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","LU0359201885.HKD","600276","LU1064130708.USD","LU2097828805.USD","01276","LU2488822045.USD","BMED","LU2148510915.USD","LU2495084118.USD","LU0359202008.SGD","IBBQ","LU0405327148.USD","LU1969619763.USD","LU2097828557.USD","BK1191","LU1655091616.SGD","LU2328871848.SGD","BK0183","BK0196","LU1580142542.USD","LU0405327494.USD","LU2097828714.EUR","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","BK0028","LU1997245177.USD","LU1997245094.SGD","LU2580892789.USD","BK0012","LU1064131003.USD","BK0239","LU2097828631.EUR","LU0359201612.USD","LU2580892862.HKD","LU1781817850.SGD","LU2289578879.USD","LU1023057109.AUD","BK0188","LU1997244956.HKD","BK0060","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649269886","title":"多地三甲医院药房化疗药环磷酰胺缺货，药企：正常供应中，发到医院还需时间","url":"https://stock-news.laohu8.com/highlight/detail?id=2649269886","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649269886?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:20","pubTimestamp":1783336802,"startTime":"0","endTime":"0","summary":"红星资本局7月6日消息，近日，经典化疗药注射用环磷酰胺缺货的消息引发关注。红星资本局注意到，在4月23日，杭州市第一人民医院官网便发布公告称环磷酰胺缺货。自5月以来，社交平台上也有不少网友称该药品难买、缺货。7月5日至6日，红星资本局以患者身份致电北京、上海、广东等地多家三甲医院，均被告知目前注射用环磷酰胺没有货。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607063795307982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","BK0196","688553","BK0028","LU1655091616.SGD","LU1997245177.USD","LU0405327148.USD","LU1064130708.USD","LU2097828714.EUR","LU1255011170.USD","LU2289578879.USD","LU2097828557.USD","600276","LU2097828474.EUR","LU1580142542.USD","LU1781817850.SGD","LU1997244956.HKD","BK1574","LU1146622755.USD","BK1161","LU2097828805.USD","LU2148510915.USD","LU1064131003.USD","LU2495084118.USD","BK0239","BK0188","LU2580892789.USD","BK0060","LU2328871848.SGD","BK0012","BK1515","09939","LU2097828631.EUR","LU0405327494.USD","LU2488822045.USD","BK0183","LU1328615791.USD","LU1820825898.SGD","LU1997245094.SGD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648665020","title":"恒瑞医药：公司将持续优化税务合规管理体系，坚守经营合规底线","url":"https://stock-news.laohu8.com/highlight/detail?id=2648665020","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648665020?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:00","pubTimestamp":1783080000,"startTime":"0","endTime":"0","summary":"证券日报网讯7月3日，恒瑞医药在互动平台回答投资者提问时表示，公司始终坚持合规经营、依法纳税，严格遵守国家税收法律法规，切实履行相关纳税义务。截至目前，公司不存在应披露未披露的重大税务补缴事项，公司将持续优化税务合规管理体系，坚守经营合规底线，保障企业稳健运营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607033793744822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU2097828631.EUR","BK0012","LU2097828557.USD","LU2097828805.USD","600276","BK0060","LU1655091616.SGD","LU1146622755.USD","LU1064131003.USD","LU1580142542.USD","LU0359201885.HKD","LU2097828474.EUR","LU2580892789.USD","LU2328871848.SGD","LU1023057109.AUD","LU0405327148.USD","LU2148510915.USD","01276","LU0405327494.USD","LU1969619763.USD","LU1997245177.USD","LU0359201612.USD","LU2488822045.USD","BK0028","BK0188","BK0196","LU2289578879.USD","LU2543165471.USD","LU1328615791.USD","LU1064130708.USD","LU1255011170.USD","LU2097828714.EUR","LU0359202008.SGD","LU1781817850.SGD","BK0183","LU2580892862.HKD","LU1820825898.SGD","BK1191","LU1997244956.HKD","LU2495084118.USD","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648504098","title":"恒瑞医药(01276)：截至6月30日累计回购1347.02万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648504098","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648504098?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:38","pubTimestamp":1782992285,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1347.02万股，已回购股份占公司总股本的比例为0.20%，购买的最高价为人民币70.00元/股，最低价为人民币45.30元/股，已支付的总金额为人民币83799.60万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU2495084118.USD","LU1023057109.AUD","LU1255011170.USD","BK0183","BK1191","LU2289578879.USD","LU0359202008.SGD","BK0060","LU1328615791.USD","LU0405327494.USD","LU1781817850.SGD","LU1820825898.SGD","LU2097828631.EUR","LU2097828557.USD","LU0359201612.USD","LU1580142542.USD","BK0188","LU1146622755.USD","BK0196","LU2097828714.EUR","BK0239","LU2580892789.USD","LU2580892862.HKD","LU1997244956.HKD","159982","LU2328871848.SGD","BK0012","399300","600276","LU1655091616.SGD","BK0028","LU1064131003.USD","LU2148510915.USD","LU2543165471.USD","LU1969619763.USD","LU1997245094.SGD","LU1997245177.USD","LU0359201885.HKD","LU1064130708.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828805.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648032985","title":"恒瑞医药：子公司注射用瑞康曲妥珠单抗上市申请获受理，并被纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2648032985","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648032985?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:01","pubTimestamp":1782982860,"startTime":"0","endTime":"0","summary":"7月2日，恒瑞医药（600276/01276）发布公告，子公司苏州盛迪亚生物医药有限公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗的药品上市许可申请获受理，且已被纳入优先审评程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791965633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","LU2097828805.USD","LU0359202008.SGD","LU2543165471.USD","LU2495084118.USD","LU1580142542.USD","LU2097828474.EUR","BK0060","LU2148510915.USD","LU1064130708.USD","01276","LU1820825898.SGD","LU0405327494.USD","LU1255011170.USD","LU1997245177.USD","LU1328615791.USD","LU1969619763.USD","BK0196","BK0239","LU0359201612.USD","LU2097828631.EUR","LU2289578879.USD","LU2580892789.USD","LU2488822045.USD","LU2097828714.EUR","BK1191","BK0012","600276","LU2328871848.SGD","LU1997244956.HKD","BK0183","BK0188","LU0359201885.HKD","LU1655091616.SGD","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU0405327148.USD","LU1023057109.AUD","LU2097828557.USD","IPOS","LU2580892862.HKD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648750366","title":"恒瑞医药：SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648750366","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648750366?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:45","pubTimestamp":1782981900,"startTime":"0","endTime":"0","summary":"南财智讯7月2日电，恒瑞医药公告，SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液收到国家药品监督管理局《药物临床试验批准通知书》，同意开展抗CTLA-4抗体SHR-8068联合阿得贝利单抗、贝伐珠单抗和TACE在不可根治肝细胞癌中的随机、双盲、多中心、III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791932797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU1820825898.SGD","LU0359201885.HKD","600276","LU1064130708.USD","LU2097828805.USD","01276","LU2488822045.USD","LU2148510915.USD","LU2495084118.USD","LU0359202008.SGD","LU0405327148.USD","LU1969619763.USD","LU2097828557.USD","BK1191","LU1655091616.SGD","LU2328871848.SGD","BK0183","BK0196","LU1580142542.USD","LU0405327494.USD","LU2097828714.EUR","LU2097828474.EUR","LU2543165471.USD","LU1255011170.USD","BK0028","LU1997245177.USD","LU1997245094.SGD","LU2580892789.USD","BK0012","LU1064131003.USD","BK0239","LU2097828631.EUR","LU0359201612.USD","LU2580892862.HKD","LU1781817850.SGD","LU2289578879.USD","LU1023057109.AUD","BK0188","LU1997244956.HKD","BK0060","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648057312","title":"港股异动 | 恒瑞医药(01276)盘中涨超6% 近期创新药艾瑞利®新增适应症 国际化出海成果颇丰","url":"https://stock-news.laohu8.com/highlight/detail?id=2648057312","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648057312?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:27","pubTimestamp":1782959232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药盘中涨超6%，截至发稿，涨3.54%，报59.9港元，成交额1.36亿港元。消息面上，近日，恒瑞医药自主研发的PD-L1抑制剂艾瑞利新增适应症获国家药品监督管理局批准，用于联合含铂化疗作为新辅助治疗，术后继续以本品作为单药辅助治疗，用于治疗可手术切除的II、IIIA和IIIB期且无已知表皮生长因子受体突变或间变性淋巴瘤激酶重排的成人非小细胞肺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1781817850.SGD","LU1255011170.USD","LU1064131003.USD","01276","LU1997244956.HKD","BK4588","LU1997245177.USD","LU2097828631.EUR","LU2097828805.USD","LU1969619763.USD","LU2097828474.EUR","LU2580892862.HKD","LU2495084118.USD","BK0028","LU2328871848.SGD","BK0239","LU0359201885.HKD","600276","LU1146622755.USD","BK0012","LU0405327148.USD","LU1328615791.USD","LU2543165471.USD","LU1064130708.USD","LU1580142542.USD","BK1161","VXUS","BK0060","BK0196","LU0405327494.USD","BK0183","BK1191","LU2097828714.EUR","LU2289578879.USD","LU0359202008.SGD","159992","LU2148510915.USD","LU2488822045.USD","BK1574","06978","LU1820825898.SGD","BK0188","LU0359201612.USD","LU1655091616.SGD","LU2097828557.USD","LU2580892789.USD","LU1997245094.SGD","BK4585","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191321586","title":"恒瑞医药旗下恒宜®获批在中国上市，作为创新性环孢素滴眼液用于治疗干眼症","url":"https://stock-news.laohu8.com/highlight/detail?id=1191321586","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191321586?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:00","pubTimestamp":1782795615,"startTime":"0","endTime":"0","summary":"恒瑞医药的恒宜®（Heng Yi®）已在中国获得批准，作为一种创新性的环孢素滴眼液，用于治疗干眼症。这一新药获批标志着公司在眼科治疗领域取得了重要进展，有望为国内众多干眼症患者提供新的治疗选择。环孢素作为一种免疫抑制剂，在眼部局部应用时，可帮助减轻炎症反应，从而改善干眼症状。该产品的上市将进一步丰富恒瑞医药的产品管线，并可能在未来为其业绩增长贡献动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU2097828557.USD","LU2148510915.USD","LU2580892862.HKD","LU1655091616.SGD","BK0239","LU1064130708.USD","LU2328871848.SGD","LU1781817850.SGD","LU0405327494.USD","LU1328615791.USD","LU1969619763.USD","LU1820825898.SGD","LU1146622755.USD","LU2580892789.USD","LU2289578879.USD","LU2495084118.USD","LU1255011170.USD","LU1580142542.USD","600276","BK0012","BK0183","BK0060","LU2488822045.USD","LU0405327148.USD","LU2097828714.EUR","BK0196","LU1997245094.SGD","LU1997245177.USD","BK0188","LU2097828631.EUR","LU2097828805.USD","LU1997244956.HKD","LU2097828474.EUR","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784605757590,"stockEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":0.1477},{"period":"3month","weight":0.0009},{"period":"6month","weight":-0.0716},{"period":"1year","weight":-0.0504},{"period":"ytd","weight":-0.0633}],"compareEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0719},{"period":"3month","weight":-0.0707},{"period":"6month","weight":-0.0779},{"period":"1year","weight":0.0741},{"period":"ytd","weight":-0.0435}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}